The development of the cytotoxic T-lymphocyte-associated protein 4 inhibitor ipilimumab
and its approval in 2011 for the treatment of metastatic melanoma has heralded a new era in …

Melanomas arising in the uveal tract of the eye are a rare form of the disease with a biology
and clinical phenotype distinct from their more common cutaneous counterparts. Treatment …

Prostate cancer is a leading cause of cancer-related death in men worldwide. Aberrant
signaling in the androgen pathway is critical in the development and progression of prostate …

Background Enzalutamide is an oral androgen-receptor inhibitor that prolongs survival in
men with metastatic castration-resistant prostate cancer in whom the disease has progressed …

Background The programmed death 1 (PD-1) receptor is a negative regulator of T-cell
effector mechanisms that limits immune responses against cancer. We tested the anti–PD-1 …

Background Uveal melanoma is a disease that is distinct from cutaneous melanoma, with a
low tumor mutational burden and a 1-year overall survival of approximately 50% in patients …

Background The anti-programmed-death-receptor-1 (PD-1) antibody pembrolizumab has
shown potent antitumour activity at different doses and schedules in patients with melanoma. …

Background Enzalutamide, an androgen-receptor inhibitor, has been associated with improved
overall survival in men with castration-resistant prostate cancer. It is not known whether …

Importance The programmed death 1 (PD-1) pathway limits immune responses to melanoma
and can be blocked with the humanized anti-PD-1 monoclonal antibody pembrolizumab. …

Purpose We evaluated atypical response patterns and the relationship between overall
survival and best overall response measured per immune-related response criteria (irRC) and …